Proof of Concept for Lenvatinib and Everolimus Prior to Cytoreductive Nephrectomy in Eligible Patients With Locally Advanced and Metastatic Renal Cell Carcinoma (RCC)

Trial Profile

Proof of Concept for Lenvatinib and Everolimus Prior to Cytoreductive Nephrectomy in Eligible Patients With Locally Advanced and Metastatic Renal Cell Carcinoma (RCC)

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 07 May 2018

At a glance

  • Drugs Everolimus (Primary) ; Lenvatinib (Primary)
  • Indications Renal cell carcinoma
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 27 Apr 2018 Planned initiation date changed from 1 Mar 2018 to 1 Jul 2018.
    • 08 Jan 2018 Planned initiation date changed from 1 Dec 2017 to 1 Mar 2018.
    • 01 Nov 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top